Journal of AdvancedMedical and Dental Sciences Research

Background: The present study was conducted for evaluating serum beta-2 microglobulin levels in breast cancer patients. Materials & methods: A total of 50 breast cancer patients and 50 healthy controls were enrolled in the present study. Patients diagnosed with clinically and histologically confirmed cases of breast cancer above 25 years of age were included while patients with history of treatment of malignancy were excluded. All the patients included in the study signed a consent form.To estimate serum beta-2 microglobulin, specimens were collected in a 5 ml syringe from ante cubital vein. Blood was then allowed to clot and the serum was separated by centrifugation. The serum was analyzed for levels ofbeta-2 microglobulin by enzyme-linked immunosorbent assay. Results: Mean serum levels of beta-2 microglobulin among patients with breast cancer was 4.23 mg/L while among healthy controls, it was found to be 1.38 mg/L. While comparing the results statistically, significant results were obtained. Conclusion: Beta-2 microglobulin levels are significantly altered in breast cancer patients highlighting their role in the pathogenesis of the disease.